SuperworthCG Oncology EPS CGON
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$2.70
- Latest quarter, Q2 FY26
- −$0.90
- Fiscal year 2025
- −$2.08
CG Oncology's earnings per share was −$2.70 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.90.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.08 | n/a |
| FY2024 | −$1.40 | n/a |
| FY2023 | −$15.51 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.90 | n/a | −$2.70 | |
| Q1 FY26 | −$0.71 | n/a | −$2.34 | |
| Q4 FY25 | −$0.52 | n/a | −$2.08 | |
| Q3 FY25 | −$0.57 | n/a | −$2.02 | |
| Q2 FY25 | −$0.54 | n/a | −$1.75 | |
| Q1 FY25 | −$0.45 | n/a | −$1.49 | |
| Q4 FY24 | −$0.46 | n/a | −$1.40 | |
| Q3 FY24 | −$0.30 | n/a | −$5.30 | |
| Q2 FY24 | −$0.28 | n/a | −$9.00 | |
| Q1 FY24 | −$0.36 | n/a | −$12.65 | |
| Q4 FY23 | −$4.36 | n/a | −$15.51 | |
| Q3 FY23 | −$4.00 | n/a | n/a |
Against its peers
Companies in Biotechnology nearest CG Oncology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CGONCG Oncology | −$2.70 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| VCELVericel | $0.46 | +283% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| Peer median | $3.27 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CG Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.